Sol-Gel Technologies to host KOL investor event on SGT-610 for Gorlin syndrome
SLGL•Sol-Gel Technologies will host a KOL investor event on SGT-610 (patidegib gel, 2%) on Oct. 14, 2026, in New York. The discussion will focus on Gorlin syndrome disease burden and the lack of effective therapies.
1. Investor event
Sol-Gel Technologies will host a KOL investor event on SGT-610 (patidegib gel, 2%) on Oct. 14, 2026, in New York. Discussion will focus on Gorlin syndrome disease burden, highlighting the lack of effective therapies.
